CareDx (CDNA) has caught investor attention after reporting second quarter results that showed year over year improvements in revenue and profitability, alongside higher full year 2026 revenue guidance and an employee stock offering filing.

The earnings beat and higher 2026 revenue guidance appear to have been a key catalyst for CareDx, with a 1 day share price return of 14.72% and a 30 day share price return of 49.74%. That adds to a 1 year total shareholder return of 257.69% and a 3 year total shareholder return of very large magnitude, although the 5 year total shareholder return is still 46.39% lower.

If CareDx’s move has you looking at what else is working in healthcare technology, it can be useful to scan other transplant and diagnostics peers, including those using AI tools in care pathways, through our 41 healthcare AI stocks

The latest jump in CareDx shares follows a sharp swing from quarterly loss to profit and higher 2026 revenue guidance. Is the valuation now mainly reflecting that business reset, or a surge in optimism that could prove fragile?

Most Popular Narrative: 23.5% Overvalued

CareDx last closed at $43.71 compared with a most widely followed fair value estimate of $35.40. This suggests the current share price sits well above that narrative view while still relying on a relatively modest discount rate of 7.13% applied to future cash flows.

Significant progress in payer coverage including millions of new covered lives, expanded in-network status, and the implementation of a unique CPT code for AlloSure indicates a catalyst for sustained increases in ASP (average selling price) and recurring revenue streams, which can directly enhance future profitability and margin expansion.

Want to understand what kind of revenue path and margin profile would justify that fair value gap for CareDx. The narrative leans on recurring testing volumes, richer reimbursement, and a future earnings multiple usually reserved for faster growing sectors. Curious which assumptions carry the most weight in that model and how sensitive the outcome is to even small changes in growth or profitability.

Result: Fair Value of $35.40 (OVERVALUED)

However, the CareDx narrative still hinges on Medicare reimbursement staying supportive and on execution in AlloSure and HeartCare, where any setback could quickly reset expectations.

Another View On CareDx Using Cash Flows

While the most followed CareDx narrative points to a fair value of $35.40 and labels the stock as overvalued, the Simply Wall St DCF output points the other way. On that model, CareDx at $43.71 is trading about 90% below an estimated future cash flow value of $445.26. Which lens do you trust more when the signals clash this sharply?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CareDx for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mixed signals on CareDx might leave you torn. Use the data, stress test the assumptions, and then weigh up the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond CareDx?

If CareDx has sharpened your focus on stock selection, do not stop here. Use the screener to spot other opportunities that fit your risk and return preferences.

• Target dependable cash generators with steady fundamentals by scanning companies in the solid balance sheet and fundamentals stocks screener (45 results).
• Hunt for quality at a reasonable price by reviewing companies highlighted in the 55 high quality undervalued stocks.
• Build a more resilient portfolio by checking stocks flagged in the 81 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.